Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma (ALPHA2)

Multiple Cancer Types

The purpose of the ALPHA-2 study is to assess the safety, efficacy, and cell kinetics of
ALLO-501A in adults with relapsed or refractory large B-cell lymphoma after a lymphodepletion
regimen comprising fludarabine, cyclophosphamide, and ALLO-647
Lymphoma, Phase I
I/II
Oluwole, Olalekan
NCT04416984
VICCCTTP20118

To learn more about any of our clinical
trials, call 615-936-8422.